4746 — Formosa Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Formosa Laboratories, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,760	3,075	3,142	3,766	4,360
Cost of Revenue
Gross Profit	825	945	971	1,390	1,923
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	2,735	3,047	3,310	3,602	3,685
Operating Profit	24.4	28	-168	163	675
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-40.2	361	1,088	333	142
Provision for Income Taxes
Net Income After Taxes	-41.1	329	1,044	217	-52.3
Minority Interest
Net Income Before Extraordinary Items
Net Income	11.6	400	1,249	409	126
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	11.6	400	1,254	409	126
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.126	3.39	10.3	3.39	1.05
Dividends per Share